Physician profile
Lisa Rapp
NPI 1801306766
$363.92
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $364.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $82.96 | 2022 | |
| Janssen Pharmaceuticals, INC | $79.44 | 2022 | |
| Abbott Laboratories | $49.27 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.02 | 2022 | |
| Amgen INC. | $29.39 | 2022 | |
| Sunovion Pharmaceuticals INC. | $27.17 | 2022 | |
| Sanofi-Aventis U.S. LLC | $21.34 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $16.02 | 2022 | |
| Lilly USA, LLC | $13.31 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Rapp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.